Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
bioRxiv (2022) - Comments
doi: 10.1101/2022.06.13.22276211 

Theodoros Karampitsakos, Ourania Papaioannou, Panagiota Tsiri, Matthaios Katsaras, Andreas Katsimpris, Andreas P. Kalogeropoulos, Elli Malakounidou, Eirini Zarkadi, Georgios Tsirikos, Vasiliki Georgiopoulou, Vasilina Sotiropoulou, Electra Koulousousa, Charikleia Chourpiliadi, Apostolos Matsioulas, Maria Lagadinou, Fotios Sampsonas, Karolina Akinosoglou, Markos Marangos, Argyris Tzouvelekis